Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 61

Results For "cancer"

1028 News Found

Apollo launches Genomics Institute in Chennai
Biotech | April 25, 2023

Apollo launches Genomics Institute in Chennai

Apollo continues to invest in genomics technology and research for better patient care


USFDA lifts clinical hold on Phase 3 investigational new drug application for MaaT013
Drug Approval | April 24, 2023

USFDA lifts clinical hold on Phase 3 investigational new drug application for MaaT013

This is the first time the Agency has authorized the Phase 3 clinical evaluation in the U.S of a microbiota-based live biotherapeutic based on a pooling technology


Enterprise Informatics central to solving productivity, staff and patient experience challenges, says Philips
Digitisation | April 18, 2023

Enterprise Informatics central to solving productivity, staff and patient experience challenges, says Philips

Digitization has unleashed a flood of data that presents a huge opportunity but is also overwhelming clinicians, nurses, and administrators


Vaniam appoints Paula Franson to lead Clinical Strategy & Solutions
People | April 18, 2023

Vaniam appoints Paula Franson to lead Clinical Strategy & Solutions

Franson will help biopharma clients design a phased approach to inform and execute clinical development plans


Ascentage presents results of studies underscoring exploratory efforts in potential
Diagnostic Center | April 18, 2023

Ascentage presents results of studies underscoring exploratory efforts in potential

The data highlight the three drug candidates' potential for clinical development and promising synergistic utilities in new indications


DualityBio collaborates with BioNTech to accelerate development of differentiated antibody-drug conjugate therapeutics
Biotech | April 18, 2023

DualityBio collaborates with BioNTech to accelerate development of differentiated antibody-drug conjugate therapeutics

WuXi Bio provided technical services, based on the companies' versatile integrated service platforms, to support various manufacturing and process development activities of these ADC product candidates.


Moderna and Merck announce an investigational individualized neoantigen therapy
Diagnostic Center | April 17, 2023

Moderna and Merck announce an investigational individualized neoantigen therapy

mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 44% compared to KEYTRUDA alone in stage III/IV melanoma patients


Alpenglow Biosciences and Mayo Clinic collaborate to advance pathology and drug development through 3D spatial biology
Diagnostic Center | April 15, 2023

Alpenglow Biosciences and Mayo Clinic collaborate to advance pathology and drug development through 3D spatial biology

Alpenglow has created an end-to-end 3D spatial biology solution including patented high-throughput 3D imaging


FDA accepts application for Merck’s Keytruda plus chemotherapy as first-line treatment for metastatic gastric
Drug Approval | April 14, 2023

FDA accepts application for Merck’s Keytruda plus chemotherapy as first-line treatment for metastatic gastric

Acceptance based on results from the Phase 3 KEYNOTE-859 trial, which showed significant overall survival benefit in these patients with HER2-negative disease, regardless of PD-L1 expression


mRNA-4157/V940in combination with Keytruda receives PRIME scheme designation from EMA
Drug Approval | April 07, 2023

mRNA-4157/V940in combination with Keytruda receives PRIME scheme designation from EMA

Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial and unmet need for additional therapeutic options for certain types of melanoma